TriSalus today said it appointed Steven Katz as chief medical officer.
Katz will be responsible for overseeing the company’s clinical development strategy in the treatment of solid tumors. He has served as TriSalus’s chief medical advisor and chairperson of its scientific advisory board since 2018.
“We are thrilled to have Steven join TriSalus as a member of our leadership team and one who will advance our goal of improving outcomes for patients with solid pancreatic and liver tumors,” president and CEO Mary Szela said in a news release. “Steven’s scientific acumen and clinical experience are second to none, but it’s his relentless commitment to eradicating solid tumors by embracing new approaches that will make the most lasting impact on overcoming one of the greatest challenges in cancer care.”
Prior to joining the company, Katz completed fellowships in immunology and surgical oncology at the Memorial Sloan-Kettering Cancer Center in New York, where he also served as the chief administrative fellow. He has also been the principal investigator for five solid tumor CAR-T trials and has invented numerous cell therapy products and methods currently under testing or development, according to TriSalus.
“Joining TriSalus will allow me to leverage my experiences as a surgeon, clinician and scientist to realize my ultimate goal – transforming outcomes for solid tumor patients with metastatic disease. New therapies are improving the way in which we treat cancer, but critical barriers in solid tumors prevent optimal delivery and performance of therapeutics,” Katz said. “I can’t wait to continue our work as a member of the TriSalus team. We’re focused on integrating delivery technology that can deliver therapeutic directly to the site of disease with therapeutic agents that both kill cancer cells and stimulate the body’s immune system in the fight. Through our relationships with exceptional academic clinical sites, we can rapidly initiate and execute clinical trials using this novel approach.”
